Cellular Biomedicine Group Inc

0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS

Case Summary
Company Name: Cellular Biomedicine Group Inc
Stock Symbol : (NASDAQ: CBMG)
Class Period Start: 06/18/2014
Class Period End: 04/07/2015
Lead Plaintiff motion: 06/22/2015
Date Filed: 04/21/2015
Type of Case: Securities Class Action
Court: U.S. District Court for the Northern District of California
Summary:

Thieler Law Corp advises investors with losses exceeding $100,000 of the June 22, 2015 lead plaintiff deadline in a class action lawsuit filed against Cellular Biomedicine Group Inc (NASDAQ: CBMG) (“Cellular Biomedicine” or “the Company”). The suit is pending in the U.S. District Court for the Northern District of California and investors, who purchased Cellular Biomedicine securities between June 18, 2014 and April 7, 2015, have until June 22, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Cellular Biomedicine securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com.  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Cellular Biomedicine Group Inc had achieved its valuation of $500 million by using paid stock promoters, without disclosing that use of such promoters in its regulatory filings, that the Company’s "Car-T" technology had experienced patient deaths and lacked any meaningful value; and as a result, the Company’s financial statements were materially false and misleading during the Class Period.

On April 7, 2015, a report was published on Cellular Biomedicine Group, which alleged that it has achieved an unsustainable valuation with paid stock promotion, that its "CAR-T" technology has experienced patient deaths and is worthless, that its founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic, and that it has multiple accounting and financial integrity issues.

On April 8, 2015, Cellular Biomedicine Group Inc (NASDAQ: CBMG) responded to the statements and allegations. Cellular Biomedicine Group Inc said that the statements and allegations are false and misleading.

Shares of Cellular Biomedicine Group Inc (NASDAQ: CBMG) declined to as low as $1.41 per share on April 8, 2015.

On April 9, 2015, NASDAQ:CBMG shares closed at $27.48 per share.

If you were negatively impacted by your investment in Cellular Biomedicine between June 18, 2014 and April 7, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185

Please find below an excerpt of the complaint filed

Cellular Biomedicine Group Inc Complaint 2015

Transactions
Buy date (mm/dd/yyyy) Number of shares Price per share
Sell date (mm/dd/yyyy) Number of shares Price per share
Please wait...